HK1046288A1 - 人erab/hadh2的肽突變體、其x射線晶體結構、以及用於鍳定其抑制劑的材料和方法 - Google Patents

人erab/hadh2的肽突變體、其x射線晶體結構、以及用於鍳定其抑制劑的材料和方法

Info

Publication number
HK1046288A1
HK1046288A1 HK02107461.3A HK02107461A HK1046288A1 HK 1046288 A1 HK1046288 A1 HK 1046288A1 HK 02107461 A HK02107461 A HK 02107461A HK 1046288 A1 HK1046288 A1 HK 1046288A1
Authority
HK
Hong Kong
Prior art keywords
hadh2
inhibitors
identification
materials
crystal structure
Prior art date
Application number
HK02107461.3A
Other languages
English (en)
Inventor
A Abreo Melwyn
S Agree Charles
A Pelletier Laura
M Aust Robert
Abraham Rejto Paul
Arthur Thomson James
J Meng Jerry
Louis Vanderpool Darin
R Kissinger Charles
Margosiak Stephen
Edward Showalter Richard
Ernesto Villafranca Jesus
Tempczyk-Russel Anna
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of HK1046288A1 publication Critical patent/HK1046288A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK02107461.3A 2000-08-18 2002-10-15 人erab/hadh2的肽突變體、其x射線晶體結構、以及用於鍳定其抑制劑的材料和方法 HK1046288A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22612300P 2000-08-18 2000-08-18

Publications (1)

Publication Number Publication Date
HK1046288A1 true HK1046288A1 (zh) 2003-01-03

Family

ID=22847647

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02107461.3A HK1046288A1 (zh) 2000-08-18 2002-10-15 人erab/hadh2的肽突變體、其x射線晶體結構、以及用於鍳定其抑制劑的材料和方法

Country Status (14)

Country Link
US (2) US6964957B2 (zh)
EP (2) EP1311511A1 (zh)
JP (2) JP2004506737A (zh)
AR (1) AR035486A1 (zh)
AU (1) AU2001296854A1 (zh)
BR (1) BR0113461A (zh)
CA (2) CA2415182A1 (zh)
GT (1) GT200100169A (zh)
HK (1) HK1046288A1 (zh)
MX (1) MXPA03001455A (zh)
PA (1) PA8525801A1 (zh)
PE (1) PE20020394A1 (zh)
UY (1) UY26895A1 (zh)
WO (1) WO2002016365A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10221052A1 (de) * 2002-05-10 2003-12-04 Transmit Technologietransfer Wirkstoffe zu Therapie, Diagnostik und Prophylaxe von Erkrankungen, bei denen abnorme Proteinstrukturen auftreten
US20070219767A1 (en) * 2003-05-06 2007-09-20 Carter Daniel C Atomic coordinates of albumin drug complexes and method of use of pharmaceutical development
EP1684705A4 (en) * 2003-11-03 2008-02-20 New Century Pharmaceuticals ALBUMIN BINDING FACILITIES FOR THE EVALUATION OF MEDICAMENTAL INTERACTION EFFECTS AND METHOD FOR ASSESSING OR DESIGNING MEDICAMENT BASED ON THEIR ALBUMIN BONDING PROPERTIES
US20080274975A1 (en) * 2004-04-12 2008-11-06 The Trustees Of Columbia University In The City Of New Yourk Methods and Compositions for Inhibiting Abad/Abeta Protein Interaction
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
ES2662868T3 (es) * 2004-09-24 2018-04-10 University Of Maryland, Baltimore Procedimiento para el tratamiento de una intoxicación por una sustancia organofosforada
WO2010118367A2 (en) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
TWI770525B (zh) 2014-12-30 2022-07-11 美商瓦洛健康公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
JP2018504431A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのチエノピリミジノン
JP2018504432A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのイソチアゾロピリミジノン、ピラゾロピリミジノン及びピロロピリミジノン
EP3253738A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
WO2023146880A1 (en) * 2022-01-25 2023-08-03 Board Of Regents Of The University Of Nebraska Functionalized allopurinol derivatives for treatment of alzheimer's disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3165520A (en) 1965-01-12 Certificate of correction
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
EP0347146B1 (en) 1988-06-16 1993-09-01 Smith Kline & French Laboratories Limited Fused pyrimidine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
US5109119A (en) * 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5322933A (en) * 1992-05-07 1994-06-21 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Crystal structure of TGF-β-2
PH31122A (en) 1993-03-31 1998-02-23 Eisai Co Ltd Nitrogen-containing fused-heterocycle compounds.
US5294611A (en) 1993-04-23 1994-03-15 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US5556778A (en) * 1994-04-28 1996-09-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Crystalline Inha Enzyme-NADH Complex
MX9606504A (es) 1994-06-16 1997-03-29 Pfizer Compuestos biciclicos.
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5656629A (en) 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US6153652A (en) 1996-11-22 2000-11-28 Elan Pharmaceuticals, Inc. N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6555651B2 (en) 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US6268479B1 (en) * 1997-03-12 2001-07-31 The Trustees Of Columbia University In The City Of New York Intracellular amyloid-beta peptide binding (ERAB) polypeptide
WO1998041526A1 (en) 1997-03-14 1998-09-24 Otsuka Pharmaceutical Co., Ltd. Novel pyrimidine derivative
WO1998049166A1 (en) 1997-04-25 1998-11-05 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
US6020162A (en) * 1997-06-13 2000-02-01 The Rockefeller University Crystal of a protein-ligand complex containing an N-terminal truncated eIF4E, and methods of use thereof
US5872011A (en) * 1997-06-13 1999-02-16 The Rockefeller University Crystal of a protein-ligand complex containing an N-terminal truncated eIF4E, and methods of use thereof
CA2314355A1 (en) 1997-12-13 1999-06-24 Bristol-Myers Squibb Company Use of pyrazolo ¢3,4-b! pyridine as cyclin dependent kinase inhibitors
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
GB9822238D0 (en) 1998-10-12 1998-12-09 Pfizer Ltd Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof
AUPP672198A0 (en) * 1998-10-23 1998-11-19 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
MXPA01010490A (es) 1999-06-10 2005-05-27 Warner Lambert Co Derivados rodanina para usarse en un metodo de inhibicion de la agregacion de proteinas amiloides y la formacion de imagenes de los depositos amiloides.
WO2000076988A1 (en) 1999-06-10 2000-12-21 Warner-Lambert Company Rhodanine derivatives and their use in inhibiting and imaging amyloids
AP1398A (en) 1999-06-10 2005-04-21 Warner Lambert Co Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives.
JP2003507013A (ja) 1999-08-13 2003-02-25 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク βシートフィブリルのＲＡＧＥへの結合を阻害する方法及びその結果

Also Published As

Publication number Publication date
AU2001296854A1 (en) 2002-03-04
BR0113461A (pt) 2003-07-01
CA2415182A1 (en) 2002-02-28
GT200100169A (es) 2002-05-16
WO2002016365A1 (en) 2002-02-28
US6964957B2 (en) 2005-11-15
EP1311511A1 (en) 2003-05-21
CA2354653A1 (en) 2002-02-18
US20020065292A1 (en) 2002-05-30
MXPA03001455A (es) 2004-05-04
PA8525801A1 (es) 2002-08-29
UY26895A1 (es) 2002-04-26
AR035486A1 (es) 2004-06-02
JP2004506737A (ja) 2004-03-04
PE20020394A1 (es) 2002-06-21
JP2002360269A (ja) 2002-12-17
US20020132319A1 (en) 2002-09-19
EP1223176A3 (en) 2002-10-23
EP1223176A2 (en) 2002-07-17

Similar Documents

Publication Publication Date Title
AU8079901A (en) Promyostatin peptides and methods of using same
AU2003267124A8 (en) Bh3 peptides and method of use thereof
IL162087A0 (en) Implantable intraluminal protector device and method of using same forstabilizing atheromas
AU2001245770A1 (en) Bone setting apparatus and method
AU4720701A (en) Improved method and apparatus for sampling cervical tissue
HK1046288A1 (zh) 人erab/hadh2的肽突變體、其x射線晶體結構、以及用於鍳定其抑制劑的材料和方法
AU2001275141A1 (en) Alerting device and method for reminding a person of a risk
AU2001286033A1 (en) Inflatable mattress system and method of use thereof
EP1362235A4 (en) APPARATUS AND METHOD FOR MICRODOSAGES OF PEPTIDES OR PROTEINS
AU8235601A (en) Dispenser and method of use
IL153687A0 (en) Composition and method for enhancing elasticity of tissue
IL138946A0 (en) Method for the identification of peptides and proteins
AU2000242290A1 (en) Apparatus and method for surgical fastening
AU2001291994A1 (en) Dipeptide ligands of the npff receptor for treating pain and hyperalgesia
AU3755999A (en) Proteins that direct the secretion of virulence proteins and vaccines comprisingthem
GB0121776D0 (en) Television system and method of use thereof
AU2002352036A8 (en) Method and device for the continuous testing of materials
AU2002343013A1 (en) Sequence variants of the human growth hormone gene and methods for detection
AU2000259049A1 (en) Histidyl-proline diketopiperazine and method of use
HUP0203676A3 (en) Pharmaceutical composition and method for treatment of diabetes
GB0129001D0 (en) System and method of material management
GB0211218D0 (en) Cosmetic method and apparatus for use therein
GB0125740D0 (en) Mattress system and method of use thereof
PL329663A1 (en) Novel peptide derivatives of analgesic properties and method of obtaining them
AUPQ692200A0 (en) Vaccines and methods for the treatment of human melanoma